William D. Waddill Protagonist Therapeutics, Inc (PTGX) insider trading activity

William D. Waddill is Director of Protagonist Therapeutics, Inc. Currently has a direct ownership of 5,130 shares of PTGX, which is worth approximately $390,700. The most recent transaction as insider was on Oct 10, 2025, when has been sold 12,000 shares (Common Stock) at a price of $78.53 per share, resulting in proceeds of $942,360. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 5.13K

60.93% 3M change

57.25% 12M change

Total Value Held $390,700

William D. Waddill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Oct 10 2025	SELL Open market or private sale	$942,360 $78.53 p/Share	12,000 Reduced 70.05%	5,130 Common Stock
Oct 10 2025	BUY Exercise of conversion of derivative security	$83,760 $6.98 p/Share	12,000 Added 41.19%	17,130 Common Stock
Sep 22 2025	SELL Open market or private sale	$257,000 $64.25 p/Share	4,000 Reduced 43.81%	5,130 Common Stock
Aug 27 2025	SELL Open market or private sale	$237,000 $59.25 p/Share	4,000 Reduced 30.46%	9,130 Common Stock
Mar 17 2025	SELL Open market or private sale	$217,000 $54.25 p/Share	4,000 Reduced 23.35%	13,130 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	5,130 Added 23.05%	17,130 Common Stock
Sep 10 2024	SELL Open market or private sale	$360,000 $45.0 p/Share	8,000 Reduced 40.0%	12,000 Common Stock
Sep 10 2024	BUY Exercise of conversion of derivative security	$103,040 $12.88 p/Share	8,000 Added 28.57%	20,000 Common Stock
Jul 24 2024	SELL Open market or private sale	$320,000 $40.0 p/Share	8,000 Reduced 40.0%	12,000 Common Stock
Jul 24 2024	BUY Exercise of conversion of derivative security	$103,040 $12.88 p/Share	8,000 Added 28.57%	20,000 Common Stock
Jun 07 2024	SELL Open market or private sale	$280,000 $35.0 p/Share	8,000 Reduced 40.0%	12,000 Common Stock
Jun 07 2024	BUY Exercise of conversion of derivative security	$103,040 $12.88 p/Share	8,000 Added 28.57%	20,000 Common Stock
Mar 01 2024	SELL Open market or private sale	$406,636 $31.34 p/Share	12,975 Reduced 51.95%	12,000 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$79,017 $6.09 p/Share	12,975 Added 34.19%	24,975 Common Stock
May 03 2022	BUY Exercise of conversion of derivative security	$103,080 $8.59 p/Share	12,000 Added 50.0%	12,000 Common Stock

Also insider at

ARWR

ARROWHEAD PHARMACEUTICALS, INC. Healthcare

Director

ANNX

Annexon, Inc. Healthcare

TSBX

Turnstone Biologics Corp.

WDW